Prosecution Insights
Last updated: April 19, 2026
Application No. 17/890,533

Oral Care Compositions For Gum Health

Non-Final OA §103
Filed
Aug 18, 2022
Examiner
HOLLOMAN, NANNETTE
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Procter & Gamble Company
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
2y 11m
To Grant
83%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allow Rate
469 granted / 778 resolved
At TC average
Strong +23% interview lift
Without
With
+22.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
19 currently pending
Career history
797
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
52.6%
+12.6% vs TC avg
§102
18.9%
-21.1% vs TC avg
§112
18.2%
-21.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 778 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Election/Restrictions Applicant’s election without traverse of Group II, claims 13-24 in the reply filed on 10/13/2025 is acknowledged. Claims 1-12 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 10/13/2025. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 13 and 15-23 are rejected under 35 U.S.C. 103 as being unpatentable over Osborne et al. (US Patent Pub. 2007/0196296) in view of Vilantonio et al. (Appl. Phys. Rev 8, 23 June 2021, pp. 1-15). Osborne et al. disclose a personal care composition comprising one or more active components ([0007). Osborne et al. disclose the composition comprises a retinoid, such as retinol and amino acid, such as the pentapeptide lys-thr-thr-lys-ser ([0063]-[0068]). Osborne et al. disclose the personal care composition can be in the form of an oil-in-water emulsion ([0145]). Osborne et al. disclose the composition comprises active components such as sodium PEG-7 olive oil carboxylate ([0045]). Osborne et al. disclose the composition comprises a metal ion source such as zinc oxide ([0133]). Osborne et al. differs from the instant claims insofar as they do not disclose a jammed oil-in-water emulsion. Vitantoni et al. disclose jammed emulsions comprising continuous and discontinuous phases used for personal care that have higher stability, are made to have minimal environmental impacts and are inexpensive to form (Introduction and Outlook). It would have been obvious before the effective filing date of the claimed invention to have formed the emulsions of Osbourne et al. into jammed oil-in-water emulsions motivated by the desire to have higher stability, are made to have minimal environmental impacts and are inexpensive to form as taught by Vilantoni. Claim(s) 14 and 24 are rejected under 35 U.S.C. 103 as being unpatentable over Osborne et al. (US Patent Pub. 2007/0196296) in view of Vilantonio et al. (Appl. Phys. Rev 8, 23 June 2021, pp. 1-15) as applied to claims 13 and 15-23 above, further in view of Sarkar et al. (US Patent Pub. 20130171080). Osborne in view of Vilantonio is discussed above and differs from the instant claims insofar as they do not disclose mineral oil, petrolatum, coconut oil, or combinations thereof or an emulsifier comprising polysorbate, an alkyl sulfate, or combinations thereof. Sarkar et al. disclose personal care compositions comprising at least one personal care component (Abstract). Sarkar et al. disclose the composition is an emulsion having a continuous aqueous phase; wherein the composition comprises polysorbate and mineral oil ([0047]). It is prima facie obviousness to select a known material based on its suitability for its intended use. Also, established precedent holds that it is generally obvious to add known ingredients to known compositions with the expectation of obtaining their known function. MPEP 2144.07. Therefore, it would have been obvious to have used polysorbate and mineral oil in the emulsion of Osborne in view of Vilantonio since they are known components of emulsion formulations. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to NANNETTE HOLLOMAN whose telephone number is (571)270-5231. The examiner can normally be reached Monday-Friday 9am-6pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana S. Kaup can be reached at 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /NANNETTE HOLLOMAN/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Aug 18, 2022
Application Filed
Feb 04, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594224
Oral Care Compositions and Methods of Use
2y 5m to grant Granted Apr 07, 2026
Patent 12582588
SOLID COSMETIC COMPOSITION FOR BLOCKING ULTRAVIOLET RADIATION HAVING WATER RESISTANCE AND CLEANSING PROPERTIES
2y 5m to grant Granted Mar 24, 2026
Patent 12582587
SUNSCREEN COMPOSITION AND METHODS OF PROTECTION FROM ULTRAVIOLET AND VISIBLE LIGHT
2y 5m to grant Granted Mar 24, 2026
Patent 12576027
DICLOFENAC TOPICAL FORMULATION WITH A HIGH ABSORPTION RATE
2y 5m to grant Granted Mar 17, 2026
Patent 12576153
PRESERVATIVE SYSTEMS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
83%
With Interview (+22.9%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 778 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month